Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial

JAMA

Volumn 308, Issue 2, 2012, Pages 147-156

  Neoptolemos, John P ^a   Moore, Malcolm J ^b   Cox, Trevor F ^a   Valle, Juan W ^c   Palmer, Daniel H ^d   McDonald, Alexander C ^e   Carter, Ross ^f   Tebbutt, Niall C ^g   Dervenis, Christos ^h   Smith, David ⁱ   Glimelius, Bengt ^j   Charnley, Richard M ^k   Lacaine, François ^l   Scarfe, Andrew G ^m   Middleton, Mark R ⁿ   Anthoney, Alan ^o   Ghaneh, Paula ^a   Halloran, Christopher M ^a   Lerch, Markus M ^p   Oláh, Attila ^q   Rawcliffe, Charlotte L ^a   Verbeke, Caroline S ^r   Campbell, Fiona ^a   Büchler, Markus W ^s   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g AUSTIN HEALTH   (Australia)

^h AGIA OLGA HOSPITAL   (Greece)

ⁱ CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^k FREEMAN HOSPITAL   (United Kingdom)

^l HÔPITAL TENON   (France)

^m CROSS CANCER INSTITUTE   (Canada)

ⁿ CHURCHILL HOSPITAL   (United Kingdom)

^o ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^p UNIVERSITY OF GREIFSWALD   (Germany)

^q Petz Aladár Hospital   (Hungary)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ALOPECIA; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIAMPULLARY ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PREAMPULLARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84863650607     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.7352     Document Type: Article

References (28)

1. Albores-Saavedra J, Hruban RH, Klimstra DS, Zamboni G. Invasive adenocarcinoma of the ampullary region. In: Bosman FT, Carneiro F, Hruban RH, Thiese ND, eds. World Health Organization Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010:87-91.
2. Berberat PO, Künzli BM, Gulbinas A, et al. An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol. 2009;35(2):187-191.
3. Henson DE, SchwartzAM,Nsouli H, Albores-Saavedra J. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of Vater share a field for carcinogenesis: a population-based study. Arch Pathol Lab Med. 2009;133(1):67-71.
4. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5625 cases from the SEER program. J Surg Oncol. 2009;100(7):598-605.
5. Hatzaras I, George N, Muscarella P, MelvinWS, Ellison EC, Bloomston M. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17(4):991-997.
6. Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and longterm prognosis. J Gastrointest Surg. 2010;14(2):379-387.
7. Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140(5):764-772. (Pubitemid 44648193)
8. O'Connell JB, Maggard MA, Manunga J Jr, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15(7):1820-1827.
9. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12(8):1422-1428.
10. Neoptolemos JP, Stocken DD, Friess H, et al European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210. (Pubitemid 38339364)
11. Neoptolemos JP, Stocken DD, Bassi C, et al European Study Group for Pancreatic Cancer. Adjuvant chemotherapywith fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-1081.
12. Pedrazzoli S, Beger HG, Obertop H, et al. A surgical and pathological based classification of resective treatment of pancreatic cancer: summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg. 1999;16(4):337-345. (Pubitemid 29376336)
13. Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumours. 5th ed. New York, NY: Wiley; 1997.
14. Carter R, Stocken DD, Ghaneh P, et al European Study Group for Pancreatic Cancer (ESPAC). Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer. 2009;124(12):2960-2965.
15. Neoptolemos JP, Dunn JA, Stocken DD, et al European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576- 1585. (Pubitemid 33101907)
16. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J AmStat Assoc. 1958;53:457-481.
17. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A Stat Soc. 1972;135:185-207.
18. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
19. Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008;8:170.
20. Sessa F, Furlan D, Zampatti C, Carnevali I, Franzi F, Capella C. Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch. 2007;451(3):649-657. (Pubitemid 47340981)
21. Ehehalt F, Rümmele P, Kersting S, et al. Hepatocyte nuclear factor (HNF) 4α expression distinguishes ampullary cancer subtypes and prognosis after resection. Ann Surg. 2011;254(2):302-310.
22. Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg. 2009;13(8):1510-1516.
23. Westgaard A, Schjølberg AR, Cvancarova M, Eide TJ, Clausen OP, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 2009;54(3):337-347.
24. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776-782.
25. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281.
26. Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, III: update on 5-year survival. J Gastrointest Surg. 2005;9(9):1191-1204.
27. Showalter TN, Zhan T, Anne PR, et al. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. J Gastrointest Surg. 2011;15(8):1411-1416.
28. de Castro SM, Kuhlmann KF, van Heek NT, et al. Recurrent disease aftermicroscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg. 2004;8(7):775-784, discussion 784.